U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07916571) titled 'Migraine Menopause Study' on Oct. 27.
Brief Summary: This study will assess whether the migraine medication eptinezumab (Vyepti) reduces migraine days in women who are in perimenopause and early menopause and who also experience night sweats and hot flashes. The study investigators will also gather information to see if there is a reduction of night sweats and hot flashes when participants are taking eptinezumab.
This study will compare the medication eptinezumab to a look-alike inactive treatment (placebo) to see if there is a difference between the two groups. In the second half of the study, all participants will receive the medi...